» Articles » PMID: 16507832

Delayed Versus Immediate Surgical Intervention and Prostate Cancer Outcome

Overview
Specialty Oncology
Date 2006 Mar 2
PMID 16507832
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

For prostate cancer patients with small, lower-grade tumors, expectant management with delayed surgical intervention (active surveillance) is a rarely used therapeutic option because the opportunity for cure may be lost. We compared outcomes of 38 patients with small, lower-grade prostate cancer in an expectant management program who underwent delayed surgical intervention at a median of 26.5 months (95% confidence interval [CI] = 17 to 32 months; range = 12.0-73.0 months) after diagnosis with 150 similar patients who underwent immediate surgical intervention at a median of 3.0 months (95% CI = 2 to 4 months; range = 1.0-9.0 months) after diagnosis. Noncurable cancer was defined as adverse pathology associated with a less than 75% chance of remaining disease-free for 10 years after surgery. Noncurable cancer was diagnosed in nine (23%) of the 38 patients in the delayed intervention cohort and in 24 (16%) of the 150 men in the immediate intervention group. After adjusting for age and prostate-specific antigen (PSA) density (i.e., PSA value divided by prostate volume) in a Mantel-Haenszel analysis, the risks of noncurable cancer associated with delayed and immediate intervention did not differ statistically significantly (relative risk = 1.08, 95% CI = 0.55 to 2.12; P = .819, two-sided Cochran-Mantel-Haenszel statistic). Age, PSA, and PSA density were all statistically significantly associated with the risk of noncurable cancer (P = .030, .013, and .008, respectively; two-sided chi-square test). Thus, delayed prostate cancer surgery for patients with small, lower-grade prostate cancers does not appear to compromise curability.

Citing Articles

Molecular and pathological subtypes related to prostate cancer disparities and disease outcomes in African American and European American patients.

Mori J, White J, Elhussin I, Duduyemi B, Karanam B, Yates C Front Oncol. 2022; 12:928357.

PMID: 36033462 PMC: 9399459. DOI: 10.3389/fonc.2022.928357.


Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study.

Salami S, Tosoian J, Nallandhighal S, Jones Jr T, Brockman S, Elkhoury F Eur Urol. 2020; 79(4):456-465.

PMID: 32631746 PMC: 7779657. DOI: 10.1016/j.eururo.2020.06.041.


The presence of primary circulating prostate cells is associated with upgrading and upstaging in patients eligible for active surveillance.

Murray N, Reyes E, Fuentealba C, Aedo S, Jacob O Ecancermedicalscience. 2017; 11:711.

PMID: 28144285 PMC: 5243134. DOI: 10.3332/ecancer.2017.711.


Prostate cancer outcomes and delays in care.

OCallaghan M, Shi Z, Kopsaftis T, Moretti K Int Urol Nephrol. 2017; 49(3):449-455.

PMID: 28083860 DOI: 10.1007/s11255-017-1508-z.


The importance of active surveillance, and immediate re-biopsy in low-risk prostate cancer: The largest series from Turkey.

Bayar G, Horasanli K, Acinikli H, Tanriverdi O, Dalkilic A, Arisan S Turk J Urol. 2016; 42(3):140-4.

PMID: 27635287 PMC: 5012439. DOI: 10.5152/tud.2016.47786.


References
1.
Cooperberg M, Lubeck D, Mehta S, Carroll P . Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003; 170(6 Pt 2):S21-5. DOI: 10.1097/01.ju.0000095025.03331.c6. View

2.
Carter H, Walsh P, Landis P, Epstein J . Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol. 2002; 167(3):1231-4. View

3.
Choo R, Klotz L, Danjoux C, Morton G, Deboer G, Szumacher E . Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol. 2002; 167(4):1664-9. View

4.
Chu K, Tarone R, Freeman H . Trends in prostate cancer mortality among black men and white men in the United States. Cancer. 2003; 97(6):1507-16. DOI: 10.1002/cncr.11212. View

5.
Han M, Partin A, Zahurak M, Piantadosi S, Epstein J, Walsh P . Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003; 169(2):517-23. DOI: 10.1097/01.ju.0000045749.90353.c7. View